|
| Press Releases |
|
 |
|
| Friday, May 27, 2022 |
|
|
Legend Capital's Portfolio Company Feima Robotics Assists China's 38th Antarctic Expedition with a Series of Civilian UAV Products |
| On April 26, 2022, the expedition ship Xuelong 2 for China's 38th Antarctic expedition berthed at the Shanghai base dock. So far, China's 38th Antarctic expedition, which lasted 174 days and traveled more than 33,000 nautical miles, has ended successfully. more info >> |
|
| Wednesday, April 27, 2022 |
|
|
Legend Capital's Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis |
| Legend Capital's portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. more info >> |
|
| Tuesday, April 26, 2022 |
|
|
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022 |
| Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022. more info >> |
|
| Sunday, April 24, 2022 |
|
|
君联资本联合创建企业朗信生物遗传性视网膜变性基因治疗产品在中国获批临床 |
| 君联资本联合创建企业朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣布，公司产品LX101注射液用于治疗RPE65双等位基因突变相关的遗传性视网膜变性（IRD）患者的临床试验申请，已获得中国国家药品监督管理局药品审评中心（CDE）批准。 more info >> |
|
|
君聯資本聯合創建企業朗信生物遺傳性視網膜變性基因治療產品在中國獲批臨床 |
| 君聯資本聯合創建企業朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣佈，公司產品LX101注射液用於治療RPE65雙等位基因突變相關的遺傳性視網膜變性（IRD）患者的臨床試驗申請，已獲得中國國家藥品監督管理局藥品審評中心（CDE）批准。 more info >> |
|
|
Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China |
| Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics more info >> |
|
| Thursday, April 7, 2022 |
|
|
君联资本所投创新型疫苗领军企业瑞科生物在港交所成功上市 |
| 3月31日，君联资本所投创新型疫苗领军企业瑞科生物（股票代码：02179.HK）在港交所成功上市。此次在港上市，成为“香港HPV疫苗第一股”、“香港新型佐剂疫苗第一股”的瑞科生物相信将会给香港资本市场注入新的活力。 more info >> |
|
|
君聯資本所投創新型疫苗領軍企業瑞科生物在港交所成功上市 |
3月31日，君聯資本所投創新型疫苗領軍企業瑞科生物（股票代碼：02179.HK）在港交所成功上市。此次在港上市，成為「香港HPV疫苗第一股」、「香港新型佐劑疫苗第一股」的瑞科生物相信將會給香港資本市場注入新的活力。
more info >> |
|
|
Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully |
| On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. more info >> |
|
| Tuesday, March 8, 2022 |
|
|
从边缘走向舞台中央：君联资本所投生物技术产业链上游专精特新企业的奋斗之路 |
| 据联想控股微空间报导，「专精特新」的灵魂是创新，强调「专精特新」就是要鼓励创新。政策目标在于强化科技创新和产业链供应链韧性，加强基础研究，推动应用研究，开展补链强链专项行动，加快解决「卡脖子」难题。联想控股旗下君联资本不仅有幸参与到众多「专精特新」企业的发展中，也践行着将「前瞻性」及「硬科技」作为关键词的投资理念。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 22, 2024 22:42 JST
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
达丰设备服务有限公司 公布2024/25中期业绩
Nov 22, 2024 19:35 HKT/SGT
|
|
|
達豐設備服務有限公司 公佈2024/25中期業績
Nov 22, 2024 19:18 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 22, 2024 14:42 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 22, 2024 14:41 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 12:00: JST
|
|
|
Daeshin MC Co., Ltd.は、産業現場から公共施設まで快適な室内環境を作り出すクリーンソリューションを発表
Nov 22, 2024 12:00: JST
|
|
|
三菱重工、新たな防衛輸送用「機動舟艇」に搭載するウォータージェット推進装置の供給へ
Nov 22, 2024 11:45: JST
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2%
Nov 22, 2024 10:00 HKT/SGT
|
|
|
アレス・マネジメント、東京オフィス開設でアジア事業を拡充
Nov 22, 2024 09:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
